ProfessorAndrew McLachlan

Antimicrobial resistance and pharmacy students in Sri Lanka and Australia

Antimicrobial Stewardship Implementation in Hospitals

Conscientious Objection in Healthcare

Exploring the pharmacologic variability of myeloablative conditioning agents in children receiving haematopoietic stem cell transplantation

Exploring the role of artificial intelligence in clinical decision-making in pharmacy: past, present, and future.

Hospital pharmacists, Aboriginal and Torres Strait Islander Peoples and chronic disease: helping to close the gap

Innovative, Scalable and Affordable Interventions for the Treatment of Low Back Pain

Investigating Adverse Drug Events and Adverse Drug Withdrawal Effects Associated with Heart Failure Pharmacotherapy in Older People with Frailty

Liposomal Amphotericin B Therapeutic Drug Monitoring in Children

Metaraminol in Critical Care

Model-Informed Precision Dosing of Paracetamol in Very Preterm Neonates with Patent Ductus Arteriosus

Multifunctional Liposomal Nanoparticles for Targeted Therapy of Triple Negative Breast Cancer

Novel approaches to management of congestive heart failure in dogs and cats

Personalised dosing to minimise haematological toxicities of immunosuppressive agents in heart transplant recipients

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Factors Associated with Busulfan Clinical Pharmacology

Pharmacokinetics based individualised dosing of anti cancer therapies for elderly patients

Real-World Use and Outcomes of Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia

Safety and tolerability of Annona muricata leaf extract in people living with cancer

Sublingual Atropine for the Treatment of Clozapine-Induced Hypersalivation and Drooling

The management of pain for patients undergoing pelvic exenteration surgery

Thermoregulatory Responses to Heat in Individuals Using Common Prescription Medications

Understanding Inter-Ethnic Differences in Tyrosine Kinase Inhibitor Response

Understanding interindividual variability in response to anti-cancer drugs using modelling and simulation